EXPAREL Achieves Statistically Significant Reductions in Opioid Consumption and Pain Scores in Cesarean Section Patients
Pacira BioSciences, Inc. (PCRX)
Last pacira biosciences, inc. earnings: 2/20 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacira.com
Company Research
Source: GlobeNewswire
PARSIPPANY, N.J., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspension) in patients undergoing Cesarean section (C-section) achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption through 72 hours (P=0.05). EXPAREL also achieved statistical significance for reduction in pain intensity scores through 72 hours (P=0.05). The full study results will be submitted for publication in the peer-reviewed medical literature later this year. Importantly, the study also achieved statistical significance (P=0.05) for relevant additional endpoints pre-specified in the statistical analysis plan to better characterize the clinical benefit of the opioid reduction, including: Total opioid consumption at one and two weeks following C-sectionPercentage of opioid-spared patients, a composite endpoint, which was defined as patien
Show less
Read more
Impact Snapshot
Event Time:
PCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCRX alerts
High impacting Pacira BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
PCRX
News
- Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag [Yahoo! Finance]Yahoo! Finance
- Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee [Yahoo! Finance]Yahoo! Finance
- Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the KneeGlobeNewswire
- Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX) [Yahoo! Finance]Yahoo! Finance
- Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $45.00 price target on the stock.MarketBeat
PCRX
Earnings
- 2/29/24 - Beat
PCRX
Sec Filings
- 3/8/24 - Form 4
- 2/29/24 - Form S-8
- 2/29/24 - Form 10-K
- PCRX's page on the SEC website